Company Overview of Moderna Therapeutics, Inc.
Moderna Therapeutics, Inc. develops messenger RNA therapeutics. The company provides in vivo drug modality that produces human proteins or antibodies inside patient cells. It also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. The company focuses on disease areas, such as inherited genetic disorders, hemophilic and blood factors, and oncology. Moderna Therapeutics, Inc. has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals, Inc.; and strategic collaborations with Karolinska Institutet, Institut Pasteur, Karolinska University Hospital, and Merck. The company was incorporated in 2009 and i...
200 Tech Square
Cambridge, MA 02139
Founded in 2009
Key Executives for Moderna Therapeutics, Inc.
Founding Chief Executive Officer and Director
Co-Founder, Chairman and Member of Technology Advisory Board
Senior Vice President of Technology Strategy
Compensation as of Fiscal Year 2016.
Moderna Therapeutics, Inc. Key Developments
Moderna Therapeutics Appoints Annie Seibold Drapeau as Chief Human Resources Officer
Oct 6 16
Moderna Therapeutics announced the appointment of Annie Seibold Drapeau as chief human resources officer. In her new role, Ms. Drapeau will lead Moderna's talent and organizational strategy to support its continued growth and advancement of its mRNA drug pipeline. She currently serves as an Operating Partner at Bain Capital Private Equity, where she partners with companies across the private equity portfolio on a range of talent and organizational capability initiatives. Ms. Drapeau will join Moderna in late October and be a member of the company's executive committee, reporting to Moderna CEO Stphane Bancel. Prior to joining Bain Capital Private Equity, Ms. Drapeau served as Executive Vice President, Strategy and Talent at Iron Mountain, a $3 billion data storage and protection business with nearly 20,000 employees worldwide.
Moderna Therapeutics, Inc. Presents at Leerink Partners Rare Disease and Immuno-Oncology Roundtable Series, Sep-28-2016 01:05 PM
Sep 26 16
Moderna Therapeutics, Inc. Presents at Leerink Partners Rare Disease and Immuno-Oncology Roundtable Series, Sep-28-2016 01:05 PM. Venue: The Lotte New York Palace Hotel, New York, New York, United States.
Moderna Therapeutics to Build Fully Integrated GMP mRNA Clinical Manufacturing Facility in Norwood, Massachusetts
Sep 21 16
Moderna Therapeutics announced that it has signed a long-term lease (15 years plus renewal options) to build a Good Manufacturing Practices (GMP) clinical manufacturing facility in Norwood, Massachusetts. Moderna is committed to developing a broad array of medicines leveraging its leading mRNA platform, and to delivering on the promise of mRNA science for patients as quickly as possible. To support and manage this anticipated breadth of clinical studies, Moderna’s 200,000 square foot Norwood facility will enable the manufacture, quality, control and supply of clinical grade mRNA therapies and vaccines for Good Laboratory Practices (GLP) toxicology studies as well as Phase 1 and Phase 2 clinical studies. At the site, Moderna will carry out all manufacturing activities "from raw material production to active pharmaceutical ingredients (APIs), formulation, filling and finish. Moderna will begin initial build-out of the new facility in October 2016. The company plans to open the facility by early 2018.
Similar Private Companies By Industry
Recent Private Companies Transactions
August 10, 2016
July 6, 2016